The US Food and Drug Administration has approved Firvanq™ (vancomycin hydrochloride; CutisPharma, Inc) to treat Clostridium difficile-associated diarrhea and enterocolitis resulting from Staphylococcus aureus.

Firvanq is expected to launch on April 2, 2018. The oral solution will replace CutisPharma’s FIRST®-Vancomycin Unit-of-Use compounding kit for preparation of vancomycin oral liquid therapy. 

“Availability of an FDA-approved vancomycin oral liquid treatment will effectively allow any pharmacy to stock this therapy, and hopefully encourage third-party payer reimbursement, significantly improving accessibility and convenience for patients,” said Stuart Johnson, MD, of Loyola University Medical Center.

Continue Reading

Firvanq will be available in 25-mg/mL and 50-mg/mL doses and 150-mL and 300-mL sizes.

Related Articles


CutisPharma announces FDA approval of FIRVANQ™ [news release]. Wilmington, MA: CutisPharma, Inc. Published January 29, 2018. Accessed January 29, 2018.

This article originally appeared on Infectious Disease Advisor